Pomalidomide was approved for medical use in the United States in February 2013,[10] and in the European Union in August 2013.[8] It is available as ageneric medication.[11]
In the European Union, pomalidomide, in combination withbortezomib anddexamethasone, isindicated in the treatment of adults with multiple myeloma who have received at least one prior treatment regimen includinglenalidomide;[8] and in combination with dexamethasone is indicated in the treatment of adults with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.[8]
In the United States, pomalidomide is indicated, in combination with dexamethasone, for people with multiple myeloma who have received at least two prior therapies including lenalidomide and aproteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy;[12] and is indicated for people with AIDS-related Kaposi sarcoma after failure ofhighly active antiretroviral therapy (HAART) or in people with Kaposi sarcoma who are HIV-negative.[12][13][14][15]
The parent compound of pomalidomide, thalidomide, was originally discovered to inhibit angiogenesis in 1994.[16] Based upon this discovery, thalidomide was taken into clinical trials for cancer, leading to its ultimate FDA approval for multiple myeloma.[17] Structure-activity studies revealed that amino substituted thalidomide had improved antitumor activity, which was due to its ability to directly inhibit both the tumor cell and vascular compartments of myeloma cancers.[18] This dual activity of pomalidomide makes it more efficacious than thalidomidein vitro andin vivo.[19]
Pomalidomide directly inhibits angiogenesis and myeloma cell growth. This dual effect is central to its activity in myeloma, rather than other pathways such as TNF alpha inhibition, since potentTNF inhibitors includingrolipram andpentoxifylline do not inhibit myeloma cell growth or angiogenesis.[18]Upregulation ofinterferon gamma,IL-2 andIL-10 as well as downregulation ofIL-6 have been reported for pomalidomide. These changes may contribute to pomalidomide's anti-angiogenic and anti-myeloma activities.[citation needed]
^abcdefg"Imnovid EPAR".European Medicines Agency (EMA). 17 September 2018.Archived from the original on 27 October 2020. Retrieved21 September 2020. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
^ab"Pomalidomide".National Cancer Institute. 13 February 2013.Archived from the original on 15 January 2023. Retrieved12 May 2023. This article incorporates text from this source, which is in thepublic domain.
^abD'Amato RJ, Lentzsch S, Anderson KC, Rogers MS (December 2001). "Mechanism of action of thalidomide and 3-aminothalidomide in multiple myeloma".Seminars in Oncology.28 (6):597–601.doi:10.1016/S0093-7754(01)90031-4.PMID11740816.
^Lentzsch S, Rogers MS, LeBlanc R, Birsner AE, Shah JH, Treston AM, et al. (April 2002). "S-3-Amino-phthalimido-glutarimide inhibits angiogenesis and growth of B-cell neoplasias in mice".Cancer Research.62 (8):2300–5.PMID11956087.
^Streetly MJ, Gyertson K, Daniel Y, Zeldis JB, Kazmi M, Schey SA (April 2008). "Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation".British Journal of Haematology.141 (1):41–51.doi:10.1111/j.1365-2141.2008.07013.x.PMID18324965.S2CID37073246.
N
Y (what is this?) (verify)
This article incorporates text from this source, which is in thepublic domain.